Alkahest is focusing on chronokines, plasma fractions that the company says stave off many of the familiar diseases of aging due to their signaling effects. These fractions naturally decrease in human blood with age, and by providing a proprietary blend of them, the company intends to reduce inflammation while restoring youthful function to multiple systems, including cognition, motor function, and neurogenesis.
Alkahest is currently developing multiple therapies based on these plasma fractions. AKST4290 is in a phase 2 trial for macular degeneration and will soon be in phase 2 trials for neurodegenerative disease and inflammatory disease. GRF6019 and GRF6021 are in phase 2 trials for neurodegenerative diseases, including Parkinson’s and Alzheimer’s, and plans to begin therapies for an as-yet undisclosed disease. Alkahest also has phase 1 and 2 trials in the works for other as-yet undisclosed diseases with different drugs.
Articles: Interview with Dr. Steven Braithwaite